Agilent Technologies Inc. A
i
Market dataready · fetched 2026-11-06T19:45:56.625Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T19:45:52.391411187Z
FundamentalsSEC EDGAR · ready · as of 2026-07-31 · fetched 2026-11-06T19:45:56.204214+00:00
Agilent Technologies Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 186.61 | 38.1% | 7.8% | 164.03 | 39.2% | 6.8% |
| 25Δ | 184.16 | 37.8% | 6.7% | 166.31 | 38.4% | 5.8% |
| 30Δ | 182.06 | 37.2% | 5.8% | 168.27 | 37.8% | 5.0% |
| 35Δ | 179.97 | 36.7% | 4.9% | 170.20 | 37.3% | 4.2% |
| 40Δ | 178.33 | 36.8% | 4.3% | 171.82 | 37.3% | 3.7% |
| 45Δ | 176.70 | 36.9% | 3.7% | 173.44 | 37.4% | 3.2% |
| 50Δ | 175.06 | 37.0% | 3.2% | 175.07 | 37.4% | 2.6% |
| 55Δ | 173.44 | 37.1% | 2.8% | 176.67 | 37.0% | 2.2% |
| 60Δ | 171.81 | 37.2% | 2.4% | 178.28 | 36.6% | 1.9% |
| 65Δ | 170.19 | 37.4% | 1.9% | 179.89 | 36.2% | 1.5% |
| 70Δ | 168.18 | 38.3% | 1.6% | 182.09 | 37.3% | 1.2% |
| 75Δ | 166.12 | 39.3% | 1.3% | 184.35 | 38.6% | 0.9% |
| 80Δ | 163.25 | 42.2% | 1.1% | 186.20 | 37.1% | 0.7% |
20Δ
- Pseudo strike
- 186.61
- IV
- 38.1%
- B/E move
- 7.8%
- Pseudo strike
- 164.03
- IV
- 39.2%
- B/E move
- 6.8%
25Δ
- Pseudo strike
- 184.16
- IV
- 37.8%
- B/E move
- 6.7%
- Pseudo strike
- 166.31
- IV
- 38.4%
- B/E move
- 5.8%
30Δ
- Pseudo strike
- 182.06
- IV
- 37.2%
- B/E move
- 5.8%
- Pseudo strike
- 168.27
- IV
- 37.8%
- B/E move
- 5.0%
35Δ
- Pseudo strike
- 179.97
- IV
- 36.7%
- B/E move
- 4.9%
- Pseudo strike
- 170.20
- IV
- 37.3%
- B/E move
- 4.2%
40Δ
- Pseudo strike
- 178.33
- IV
- 36.8%
- B/E move
- 4.3%
- Pseudo strike
- 171.82
- IV
- 37.3%
- B/E move
- 3.7%
45Δ
- Pseudo strike
- 176.70
- IV
- 36.9%
- B/E move
- 3.7%
- Pseudo strike
- 173.44
- IV
- 37.4%
- B/E move
- 3.2%
50Δ
- Pseudo strike
- 175.06
- IV
- 37.0%
- B/E move
- 3.2%
- Pseudo strike
- 175.07
- IV
- 37.4%
- B/E move
- 2.6%
55Δ
- Pseudo strike
- 173.44
- IV
- 37.1%
- B/E move
- 2.8%
- Pseudo strike
- 176.67
- IV
- 37.0%
- B/E move
- 2.2%
60Δ
- Pseudo strike
- 171.81
- IV
- 37.2%
- B/E move
- 2.4%
- Pseudo strike
- 178.28
- IV
- 36.6%
- B/E move
- 1.9%
65Δ
- Pseudo strike
- 170.19
- IV
- 37.4%
- B/E move
- 1.9%
- Pseudo strike
- 179.89
- IV
- 36.2%
- B/E move
- 1.5%
70Δ
- Pseudo strike
- 168.18
- IV
- 38.3%
- B/E move
- 1.6%
- Pseudo strike
- 182.09
- IV
- 37.3%
- B/E move
- 1.2%
75Δ
- Pseudo strike
- 166.12
- IV
- 39.3%
- B/E move
- 1.3%
- Pseudo strike
- 184.35
- IV
- 38.6%
- B/E move
- 0.9%
80Δ
- Pseudo strike
- 163.25
- IV
- 42.2%
- B/E move
- 1.1%
- Pseudo strike
- 186.20
- IV
- 37.1%
- B/E move
- 0.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 33.40% | |
| 33.52% | |
| 33.25% | |
| 32.20% | |
| 32.86% | |
| 33.55% | |
| 33.90% | |
| 39.03% | |
| 35.60% | |
| 36.95% | |
| 36.82% | |
| 38.09% | |
| 29.38% | |
| 29.35% | |
| 29.79% | |
| 29.54% | |
| 28.48% | |
| 28.58% | |
| 29.78% | |
| 31.55% | |
| 31.15% | |
| 31.47% | |
| 29.91% | |
| 31.17% | |
| 30.94% | |
| 34.20% | |
| 34.25% | |
| 30.06% | |
| 32.41% | |
| 31.14% | |
| 31.51% | |
| 33.04% | |
| 33.04% | |
| 34.59% | |
| 33.06% | |
| 32.70% | |
| 32.61% | |
| 32.07% | |
| 33.74% | |
| 34.38% | |
| 34.48% | |
| 35.24% | |
| 35.00% | |
| 36.62% | |
| 35.69% | |
| 38.62% | |
| 34.23% | |
| 34.46% | |
| 35.35% | |
| 34.76% | |
| 36.93% | |
| 35.51% | |
| 36.32% | |
| 35.57% | |
| 35.73% | |
| 36.08% | |
| 37.57% |
Diagnostics & Research
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is…
More →BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
More →CDNA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
More →CRL
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell…
More →CSTL
Description unavailable
More →DGX
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains…
More →